Pediapharm to Present at Bloom Burton & Co. Healthcare Investor Conference


MONTREAL, QUEBEC--(Marketwired - April 26, 2016) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Pediapharm Inc. ("Pediapharm" or the "Company") (TSX VENTURE:PDP) has been invited to present at Bloom Burton & Co. Healthcare Investor Conference being held on May 2-3, 2016 at the Sheraton Centre Toronto Hotel in Toronto, Ontario.
The Company is scheduled to present on Tuesday, May 3, 2016 at 2:00 p.m. EDT, with several one-on-one meetings to be held throughout the conference. Management will be pleased to discuss the Company's overall business, including the exciting upcoming milestones and the on-going success of NYDA®, its current signature brand.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; and a broad pipeline of products under registration.

About the Conference :

Bloom Burton is hosting its fifth annual Healthcare Investor Conference on May 2 and 3, 2016, at the Sheraton Centre Toronto Hotel, Toronto, Canada. We will host approximately 60 of Canada's premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. The event will attract Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies, and participate in our 1-on-1 meeting system with company management.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Sylvain Chretien, President and Chief Executive Officer
Pediapharm Inc.
514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com

Roland Boivin, Chief Financial Officer
Pediapharm Inc.
514-762-2626 ext. 202
roland.boivin@pedia-pharm.com

Frank Candido
Direct Financial Strategies and Communication Inc.
514-969-5530
directmtl@gmail.com